Skip to main content

Sarah C. Palmer

(she/her/hers)

Associate

[email protected]

+1.617.348.4830

Share:

Sarah’s practice focuses on a broad range of corporate transactions, including mergers and acquisitions, venture financings, licensing/commercial technology transactions, and everyday business strategy and corporate governance matters. She represents private companies throughout their life cycles, from company formation up until they go public or engage in a sale of the company, often serving as outside general corporate counsel. Sarah’s practice spans across multiple industries, primarily technology, life sciences, and financial services. Her experience includes representing companies, venture funds, and strategic and angel investors in a wide range of financing transactions, including convertible note and Simple Agreement for Future Equity (SAFE) offerings. Sarah also represents family offices and funds in the acquisition of and investment in other businesses.

Sarah regularly guest lectures to entrepreneurs and start-ups on the topics of entity formation and early-stage financings at MIT’s Sloan School of Management.

Before joining Mintz, Sarah was an associate and summer associate in the Boston office of a global law firm, where she worked with public and private companies on general corporate and transactional matters.

During law school, Sarah served as a legal intern at Social Finance, Inc., a nonprofit that mobilizes private capital to create innovative financing programs designed to provide social benefits to communities all over the world. She also worked in the Boston office of a global custodian bank as a proxy voting & governance analyst, and spent time in-house at the Federal Reserve Bank of Boston as a legal intern.

Prior to attending law school, Sarah was a Teach For America Corps Member and spent three years as a middle school teacher in Baltimore.

Experience

  • Represented Censa Pharmaceuticals, a rare disease-focused pharmaceutical company, in its sale to PTC Therapeutics in a reverse merger IPO valued at up to $500 million.
  • Represented a telehealth company in its acquisition of another digital health company for an aggregate value of $138 million.
  • Represented Revision Military Limited, a leader in protective eyewear solutions for military and tactical use, in the sale of its eyewear business to ASGARD Partners & Co., a private equity firm based in New York, and Merit Capital Partners, a private equity firm based in Chicago
  • Represented cloud computing company Rocket Innovations, Inc. in the sale of Rocketbook, the leading smart reusable notebook brand in the United States, to BIC, a global manufacturing company of disposable consumer products such as stationery, lighters, and shavers
  • Represented a family office in the acquisition of an autism services company for an aggregate value of up to $15 million.
  • Represented Relation Therapeutics in a $15 million equity investment from GSK, part of a broader $45 million upfront collaboration that includes potential milestone payments of up to $200 million per target and tiered royalties.
  • Represented Granata Bio Corporation in its $15 million Series A+ round, supporting innovation in reproductive health.
  • Represented the University of Maryland Medical System’s spinout of Gallion Health, helping launch the first company from UMMS’s iHarbor Innovation Center.
  • Represented a medical device company in a $400,000 “friends and family” convertible note financing.
  • Represented a pharmaceutical company in a three-tranche Series A financing valued at up to $45 million.
  • Represented a life science company in its $90 million Series D financing.
  • Represented a German VC fund in its investment in a $35 million Series B financing.
  • Represented a European enterprise software company in a corporate reorganization and cross-border $20 million Series A financing.
  • Represented a drug development company in its $150 million Series A financing.
  • Represented an insurtech company in its $3 million Series Seed financing.
  • Regularly represent technology-focused strategic investors in international early- to mid-stage venture financings.
  • Regularly represent fund-incubated life science companies.
  • Represent start-up companies on formation and corporate structure, including drafting stockholders and founders agreements; form of equity incentive plans and stock option agreements; nondisclosure, non-competition and invention assignment agreements; stock restriction and stock purchase agreements; and the filing of 83(b) elections.
  • Represent education non-profit in ongoing IP licensing and commercial contract needs.
  • Advise emerging growth companies on corporate governance matters, including board composition, committee structures, fiduciary duties, and compliance with Delaware corporate law.
  • Counsel portfolio companies on day-to-day legal matters as outside general counsel, including contract review, employment matters, regulatory compliance, and strategic business decisions.
  • Structure and negotiate SAFE and convertible note financings for early-stage technology and life sciences companies, advising on valuation caps, discount rates, and conversion mechanics.
  • Represent angel investors and angel investor networks in seed-stage and early-stage financings across the technology sector.
  • Represent a large, public strategic investor in venture capital and strategic investments across the healthcare and technology sectors.
     
Read less

viewpoints

ARPA-H Commits $100 Million to Accelerate Women’s Health Research through Sprint for Women’s Health

February 28, 2024 | Alert | By Pamela Mejia, Sarah C. Palmer, Anthony DeMaio

Read about Sprint for Women’s Health, a first-of-its-kind initiative to commit $100 million for research and development in women’s health, announced by the Advanced Research Projects Agency for Health.

Read more
Read less

News & Press

Press Release Thumbnail Mintz

Mintz advised Relation Therapeutics, a technology-enabled biopharmaceutical company, on its strategic collaboration with Novartis, leading on the negotiation of an equity investment from Novartis.

Press Release Thumbnail Mintz

Mintz advised on Gallion Health’s spinout from the University of Maryland Medical System (UMMS), marking the first company to emerge from the health system’s technology and incubation studio, iHarbor Innovation Center. The Center focuses on creating technology-based solutions to common problems facing health care institutions. Gallion Health is an award-winning cloud-based digital supply chain application that was launched at UMMS four years ago. 

Press Release Thumbnail Mintz

Mintz represented Granata Bio Corporation (Granata Bio), a biopharma company focused on invigorating the $3.6B global infertility medication market, in its $15M Series A+ funding round. 

Press Release Thumbnail Mintz

Mintz advised Relation, an industry leader in deploying computation and experimentation to drug discovery, on an equity investment of $15 million from GSK in connection with two simultaneous strategic collaborations with GSK, a global biopharma company. The collaborations are aimed at advancing the development of novel therapeutics for fibrotic diseases and osteoarthritis – conditions which affect millions worldwide and which currently have few treatments addressing their root causes. 

Press Release Thumbnail Mintz

Mintz is pleased to announce that 31 attorneys have been named Massachusetts Super Lawyers and 35 attorneys have been named Massachusetts Rising Stars for 2024.

Press Release Thumbnail Mintz

CAMBRIDGE, Mass.—Mintz advised Quaise Energy, a developer of a new hybrid deep drilling technology for geothermal energy, in its recent $21 million Series A1 funding round. The deal brings Quaise’s total funding to more than $95 million. The investment will be used to scale up Quaise’s supply chain and enhance its field operations by improving geologic understanding at plant sites.

News Thumbnail Mintz
Mintz Associates Benjamin D. Stone and Sarah C. Palmer co-authored an article published by VC Experts exploring potential exit options for public benefit corporations
Read less

Events & Speaking

Speaker
Speaker
Apr
16
2019

Money for Startups

MIT Lawyer Simulation

Mintz, 1 Financial Center, Boston, MA 02111

Read less

Recognition & Awards

  • Massachusetts Super Lawyers Rising Star: Business/Corporate Transactions (2024, 2025) 

Read less

Involvement

  • Member, Boston Bar Association
  • Member, Massachusetts Bar Association
  • Greater Boston Chamber of Commerce
Read less

Sarah C. Palmer

(she/her/hers)

Associate

Boston